I-Human CYP2C19 Gene Polymorphism

I-CYP2C19 yenye yezona zinto zibalulekileyo eziguqula ii-enzymes kusapho lwe-CYP450. Ii-substrates ezininzi ze-endogenous kunye ne-2% yamayeza eklinikhi aguqulwa yi-CYP2C19, njenge-metabolism ye-antiplatelet aggregation inhibitors (njenge-clopidogrel), i-proton pump inhibitors (i-omeprazole), i-anticonvulsants, njl. Ii-polymorphisms ze-CYP2C19 gene nazo zinomahluko kubuchule be-metabolism yamayeza anxulumene nawo. Ezi nguqu ze-*2 (rs4244285) kunye ne-*3 (rs4986893) zibangela ukulahleka komsebenzi we-enzyme oguqulwe yi-CYP2C19 gene kunye nobuthathaka bobuchule be-metabolism substrate, kwaye zonyusa uxinzelelo lwegazi, ukuze kubangele iimpendulo ezimbi zamayeza ezinxulumene noxinzelelo lwegazi. *17 (rs12248560) inokunyusa umsebenzi we-enzyme oguqulwe yi-CYP2C19 gene, ukuveliswa kwee-metabolites ezisebenzayo, kwaye yonyuse ukuthintelwa kokuhlanganiswa kweeplatelet kwaye yonyuse umngcipheko wokopha. Kubantu abane-metabolism ecothayo yamayeza, ukuthatha iidosi eziqhelekileyo ixesha elide kuya kubangela ityhefu enkulu kunye nemiphumo emibi: ikakhulu umonakalo wesibindi, umonakalo wenkqubo ye-hematopoietic, umonakalo wenkqubo ye-nervous central, njl.njl., okunokukhokelela ekufeni kwiimeko ezinzima. Ngokweeyantlukwano ezahlukeneyo kwi-metabolism yeziyobisi ezifanelekileyo, ngokubanzi yahlulwe yaba ziiphenotypes ezine, ezizezi i-metabolism ekhawulezayo kakhulu (UM,*17/*17,*1/*17), i-metabolism ekhawulezayo (RM,*1/*1), i-metabolism ephakathi (IM, *1/*2, *1/*3), i-metabolism ecothayo (PM, *2/*2, *2/*3, *3/*3).